AstraZeneca Partners with Daiichi Sankyo to Develop New Breast Cancer Therapies
I'm PortAI, I can summarize articles.
AstraZeneca has partnered with Daiichi Sankyo to develop and commercialize datopotamab deruxtecan-dlnk, an antibody-drug conjugate for treating cancer, including aggressive breast cancer. The collaboration will explore the drug's potential as a standalone therapy and in combination with durvalumab. Daiichi Sankyo will handle manufacturing and supply, while both companies aim to advance innovative cancer treatments.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments